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Abstract: Actin remodelling proteins regulate cytoskeletal cell responses and are important in both
innate and adaptive immunity. These responses play a major role in providing a fine balance
in a cascade of biological events that results in either protective acute inflammation or chronic
inflammation that leads to a host of diseases including autoimmune inflammation mediated
epidermolysis bullosa acquisita (EBA). This review describes the role of the actin cytoskeleton and in
particular the actin remodelling protein called Flightless I (Flii) in regulating cellular inflammatory
responses and its subsequent effect on the autoimmune skin blistering disease EBA. It also outlines
the potential of an antibody based therapy for decreasing Flii expression in vivo to ameliorate the
symptoms associated with EBA.
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1. Epidermolysis Bullosa Acquisita (EBA)
EBA is a chronic (muco)-cutaneous autoimmune skin blistering condition with an incidence of
0.2–0.5 new cases per million per year [1]. The pathogenicity of EBA is classified by sub-epidermal
blistering and tissue bound and circulating autoantibodies at the dermal-epidermal junction against
the type VII collagen (COL7) anchoring fibrils [2,3]. EBA patients are classified into two major
subtypes: non-inflammatory mechanobullous subtype seen in 33% of patients and the more
common inflammatory EBA observed in 66% of patients, which is characterized by cutaneous
inflammation and clinically mimics other bullous dermatoses [4,5]. Currently, no controlled clinical
trials have been performed on the treatment of EBA and available treatment options involve
general immunosuppressive therapy, most commonly colchicine, and/or high doses of systemic
glucocorticoids [2], highlighting the need for development of better therapeutic options with targeted
modalities specific to EBA [6].
EBA is diagnosed based on the clinical presentation, detection of tissue bound autoantibodies
using direct immunofluorescence and detection of circulating antibodies against COL7 [5].
Patients with inflammatory EBA experience widespread vesiculobullous eruptions involving the
trunk, the extremities and skin folds often mimicking other autoimmune bullous dermatoses including
bullous pemphigoid, linear IgA, mucous membrane pemphigoid and Brunsting-Perry pemphigoid
(Figure 1) [4,6]. EBA belongs to the pemphigoid group of diseases where subepidermal loss of adhesion
results in severe blistering [1]. However, many autoimmune diseases manifest with a cutaneous
involvement. These include systemic scleroderma, systemic lupus erythematosus and autoimmune
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skin blistering diseases, e.g., pemphigus/pemphigoid, in which the autoimmune response is directed
to antigens, which are structural components of the skin. (Muco)-cutaneous blistering, directly or
indirectly caused by the autoantibody binding, is the clinical hallmark of these diseases [7,8].
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Figure 1. Clinical manifestations of inflammatory epidermal bullosa acquisita (EBA). Blisters and 
scars on the knee (A); loss of toenails (B); inflammatory blisters on the back and arms in bullous 
pemphigoid-like EBA (C); oral mucosal involvement in mucous membrane pemphigoid-like EBA (D); 
localized blisters on the cheek in Brunsting-Perry pemphigoid-like EBA (E); blisters on the buttock in 
linear IgA dermatosis-like EBA (F). Figure adapted with permission from Kim and Kim 2013 JEADV 
and modified [6]. 
Pathogenesis of EBA can be broadly divided into three distinct phases including: loss of tolerance 
to COL7 with subsequent autoantibody production; circulation of the autoantibodies in the 
bloodstream and antibody induced inflammation and blistering [5]. Studies to date have determined 
that genetics, T cells, and cytokines all play a critical role in mediating the loss of tolerance towards 
COL7 and have identified novel potential therapeutic targets for the treatment of EBA [4,9].  
The pathogenesis of autoantibody induced tissue injury in EBA is mediated by anti-COL7 antibody 
binding to COL7, followed by compliment activation, cytokine release mediating neutrophil 
infiltration, and release of elastase and reactive oxygen species following neutrophil binding to  
immune complexes [10]. Blister formation activates different signalling pathways aimed at resolving 
the cutaneous inflammation [4]. In the last decade, the development of different animals models of 
inflammatory EBA have facilitated the elucidation of the pathogenesis of this autoantibody induced, 
cell-mediated sub-epidermal disease. These models have included: In vivo antibody transfer induced 
EBA mouse model and in vivo immunization-induced EBA mouse models reviewed in [11]. 
Interestingly, studies investigating the mechanisms that underpin blistering and inflammation have 
highlighted the role of cytoskeletal proteins, particularly Flightless I, during skin blistering [12,13]. 
  
Figure 1. Clinical manifestations of inflammatory epidermal bullosa acquisita (EBA). Blisters and
scars on the knee (A); loss of toenails (B); inflammatory blisters on the back and arms in bullous
pemphigoid-like EBA (C); oral mucosal involvement in mucous membrane pemphigoid-like EBA (D);
localized blisters on the cheek in Brunsting-Perry pemphigoid-like EBA (E); blisters on the buttock in
linear IgA dermatosis-like EBA (F). Figure adapted with permission from Kim and Kim 2013 JEADV
and modified [6].
Pathogenesis of EBA can be broa l divided i to three distinc ph ses inclu ing: loss of
tolerance to COL7 with subsequent autoantibody production; circulation of t e autoantibo ies
in the bloodstream and antibody induced inflammation and blistering [5]. Studies to date have
determined that genetics, T cells, and cytokines all play a critical role in mediating the loss of
tolerance towards COL7 and have identified novel potential therapeutic targets for the treatment of
EBA [4,9]. The pathogenesis of autoantibody induced tissue injury in EBA is mediated by anti-COL7
antibody binding to COL7, followed by compliment activation, cytokine release mediating neutrophil
infiltration, and release of elastase and reactive oxygen species following neutrophil binding to
immune complexes [10]. Blister formation activates different signalling pathways aimed at resolving
the cutaneous inflammation [4]. In the last decade, the development of different animals models
of inflammatory EBA have facilitated the elucidation of the pathogenesis of this autoantibody
induced, cell-mediated sub-epidermal disease. These models have included: In vivo antibody transfer
induced EBA mouse model and in vivo immunization-induced EBA mouse models reviewed in [11].
Interestingly, studies investigating the mechanisms that underpin blistering and inflammation have
highlighted the role of cytoskeletal proteins, particularly Flightless I, during skin blistering [12,13].
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2. The Actin Cytoskeleton
The actin cytoskeleton is involved in an array of vital cellular functions and has a pronounced
influence on many aspects of skin biology [14–16]. Despite the structural role of the cytoskeleton,
it is highly dynamic and can be rapidly modified to facilitate changes in cell structure during
vesicle-organelle transport, cell-cell interactions, cell-extracellular matrix interactions and cell adhesion
and motility [17–19]. The cytoskeleton comprises a network of filamentous (F)-actin, microtubules,
intermediate filaments and stress fibres, all working together to mediate the continual remodelling,
assembly and severing needed to generate the mechanical force required for cellular contraction,
adhesion and motility [20]. The actin cytoskeleton is a key component required for cellular polarization,
force generation, and formation of membrane protrusions, lamellipodia, membrane ruffles and
focal adhesions. Actin binding proteins including both structural and adaptor signalling proteins
(vinculin, talin, paxillin, α-actinin, Focal Adhesion Kinase (FAK), Src kinase) are involved in regulating
actin organisation and polymerisation required for mediation of cell protrusions and migration [21].
Signalling of these proteins results in formation of adhesion sites with downstream signalling to small
GTPases of the Rho family regulating the actomyosin dynamics and enabling efficacy and plasticity of
leukocyte migration [22]. Integrin mediated cell-matrix adhesions, termed focal complexes develop
underneath lamellipodia and are driven by actin polymerisation. These highly dynamic structures
develop into elongated focal adhesions associated with necessary contractile stress fibres allowing cell
adhesion to the extracellular matrix. Anchoring of the polymerized stress fibres into bundles provides
the contractile force required for effective translocation of cell body during cellular migration [23].
3. The Role of the Actin Cytoskeleton in Inflammation and Autoimmune
Inflammatory Conditions
Recent discoveries have revealed that alterations in actin regulatory and remodelling proteins
can results in immune deficiency, autoimmunity and autoinflammatory disease [24]. The deficient
or aberrant expression of proteins involved in the regulation of the actin cytoskeleton has
increasingly been associated with immunodeficiency and/or autoimmune/autoinflammatory diseases.
These regulatory/remodelling actin proteins include actin nucleators (formins and Arp2/3 complex,
mDia1), nucleation promoting factors (WASp family, WAVE family, Hemapoetic protein 1),
actin stabilizing protein, actin de-polymerising protein (coronin) and actin severing proteins
(cofilin, Wdr1) [24]. In relation to inflammation mediated autoimmunity, WASp deficiency results in
defects in cellular migration and adhesion, activation and antigen presentation affecting T cells, B cells
and dendritic cells of the immune system [25], while WIP deficiency lead to defects in cell chemotaxis,
de-granulation and hyperactivity of B cells [24]. In addition, regulation of the actin cytoskeleton is
critical for intercellular interactions especially formation of immune synapses and cytotoxic T cell
apparatus as well as for inflammatory cell migration within and into the skin [26]. Leucocyte migration
from blood through interstitial tissues is essential for mounting of a successful immune response
and cell intrinsic and extrinsic factors contribute to proper positioning of the immune cells in the
context of special microenvironments [27]. Paracellular and transcellular migration of leucocytes
through a process of diapedesis involves number of molecules and mechanism linked to the actin
cytoskeleton [28]. Migration of leukocytes from blood to the site of an injury or inflammation in the
skin involves a sequence of steps including attachment to the vessel wall, locomotion along the wall
to the endothelial borders, transverse migration through the endothelium and the subendothelial
basement membrane, and migration through the interstitial tissue [28]. Several endothelial molecules
including junctional adhesion molecules, endothelial cell selective adhesion molecules and regulators of
endothelial tight junctions have been identified to control transendothelial migration of leukocytes [28].
Additionally, leukocyte perivascular extravasation, migration into the site of tissue injury and adhesion
to the extracellular matrix is governed by the polarisation of the actin cytoskeleton [27].
Actin cytoskeletal regulation has also been shown to influence the function of other inflammatory
cells including mast cells, dendritic cells, neutrophils and macrophages. Actin cytoskeletal dynamics,
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including actin filament organisation and distribution of the microtubules in mast cells is governed
by GTP-binding proteins [29]. In addition, integrity of the dendritic cell actin cytoskeleton is vital
for T cell priming and adhesion during immunological synapse formation [30] while neutrophil
contractile forces and cytoskeletal dynamics play an active biophysical role during transmigration
through endothelial cell-cell junctions [31]. In context of skin autoimmune inflammatory disease,
chemotaxis of macrophages and co-ordinated movement of keratinocytes and activated fibroblasts is
directly relevant to the functioning and dynamics of the actin cytoskeleton, including actin control of
cell polymerisation, migration and contractibility [32].
4. The Gelsolin Family of Actin Remodelling Proteins
The dynamic remodelling of the cytoskeleton is facilitated by the gelsolin family of remodelling
proteins which includes gelsolin, villin, adseverin, capG, advillin, supervillin and Flightless I [33].
Gelsolin has been shown to play a role in inflammation and specially inflammatory autoimmune
disease, with studies suggesting potential clinical applications for plasma gelsolin in diagnosis and
disease activity evaluation as patients with systemic lupus erythematosus (SLE) and rheumatoid
arthritis (RA) have significantly decreased plasma gelsolin levels compared to healthy controls [34,35].
Inhibition of the FAK, a non-receptor tyrosine kinase involved in cytoskeleton remodelling and
formation and disassembly of cell adhesion structures prevents blister formation in a mouse model
of autoimmune skin blistering disease pemphigus vulgaris [36]. Leucine Rich Repeat Flightless
Interacting Protein 2 (LRRFlp2) has recently been shown to regulate NLRP3 inflammasome activation
in a Flightless I (Flii)-dependant manner [37]. Flii has been shown to control inflammasome activation
by way of direct blocking of caspase-1 and caspase-11 and by modulating their subcellular localisation
while LRRFlp2 was found to enhance the interaction between Flii and caspase-1 therefore facilitating
the inhibitory effect of Flii on caspase-1 activation and subsequent inflammasome activity [37].
Furthermore, silencing of Flii abrogated the inhibitory effect of LRRFlp2 on NLRP3 inflammasome [37]
suggesting that an intricate balance of these actin associated cytoskeletal protein is vital in regulation
of cellular inflammatory responses, which may have implications in many kinds of diseases including
autoimmune disorders. These studies suggest an important cytoskeletal involvement in autoimmune
skin conditions. Gelsolin is secreted into plasma to severe the actin filaments that have been
released into the circulation following injury and cell necrosis using its gelsolin domain [38–40].
Plasma gelsolin is able to inactivate Pathogen-Associated Molecular Pattern (PAMPs) molecules,
like Lipopolysaccharide (LPS) and Lipoteichoic acid (LTA), resulting in decreased TLR-mediated
NF-κB activity [41,42] and a potential protective role for plasma gelsolin against inflammation.
5. Gelsolin Family Member: Flightless I (Flii)
Flii is important in multiple intracellular and extracellular processes. It is a highly conserved
multifunctional protein possessing an unique structure, containing 6 gelsolin domains and an
additional 11 tandem repeats of a 23-amino acid Leucine Rich Repeat (LRR) motif not present in
other family members [43]. Sequence analysis has revealed that Flii retains the gelsolin-like actin
binding surfaces but it is missing the calcium binding sites from its gelsolin domains 1–4, however
the functional effects of this finding is still unknown [44]. The specificity of its structure allows Flii
to use the gelsolin domain to bind and remodel (via severing, capping, and bundling) cytoplasmic
actin monomers (G-actin) and actin filaments (F-actin) and it possesses F-actin severing ability [45,46].
Unlike other members of the gelsolin family which enhance actin polymerisation, Flii inhibits actin
polymerisation [47] and associates with focal adhesions inhibiting their turnover in a Rac1 dependant
manner [48]. Unique specificity of its LRR domain allows Flii to interact with multiple signalling and
structural proteins [49] (Figure 2). The bipartite domain structure of Flii provides capacity for it to
transduce cell signalling events into remodelling of the actin cytoskeleton and Flii has been proposed
to be involved in a variety of signalling pathways [43,45,50,51].
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Secreted Flii has been detected in human plasma [52], and acute and chronic human wound fluids [52,53]. 
Flii is constitutively secreted by both fibroblasts and macrophages and this this secretion is increased 
in response to scratch wounding in fibroblasts and LPS-activated macrophages via a late 
endosome/lysosome pathway regulated by Rab7 and Stx11 [54]. Secreted Flii protein also binds LPS 
and has the ability to alter macrophage activation both intracellularly and extracellularly, leading to 
increased TNF-α cytokine secretion and altered inflammatory responses [52,54] suggesting that Flii 
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Flii is found in the nucleus, cytosol, lysosomes and like gelsolin is also a secreted protein [38–40,52].
Secreted Flii has been detected in human plasma [52], and acute and chronic human wound
fluids [52,53]. Flii is constitutively secreted by both fibroblasts and macrophages and this this secretion
is increased in response to scratch wounding in fibroblasts and LPS-activated macrophages via
a late endosome/lysosome pathway regulated by Rab7 and Stx11 [54]. Secreted Flii protein also
binds LPS and has the ability to alter macrophage activation both intracellularly and extracellularly,
leading to increased TNF-α cytokine secretion and altered inflammatory responses [52,54] suggesting
that Flii upregulation in response to wounding may be directed towards regulating inflammatory
cellular responses with unfortunate consequences on healing of wounded area. Flii also binds to
proteins other than actin, both in the cytoplasm and in the nucleus, as well as outside the cell. It is
sequestered in the cytosol by the active form of the calmodulin-dependent protein kinase type II
(CaMK-II) protein [55]. Within the nucleus it binds to a variety of coactivator complexes and to nuclear
hormone receptor molecules thereby mediating changes in transcription [56–59]. Flii, therefore, may
provide a link between cell signalling pathways and actin-dependent morphogenetic processes such
as proliferation, migration, and adhesion [60,61], all of which influence outcomes of inflammation
mediated autoimmune diseases.
6. Flii Regulation of the Inflammatory Response
Autoimmune disease develops as a response of parallel mechanisms that relate to the presence of
auto-reactive immune cell subsets and loss of immunological tolerance [62]. A key role of the immune
system, linking the innate immune responses and adaptive immunity are the germ line encoded
receptors, termed pattern recognition receptors (PRRs) [63]. These receptors are present on a variety of
immune cells and function to recognize both pathogen-associated molecular patterns (PAMPs), such as
bacterial lipopolysaccharide (LPS), and damage-associated molecular patterns (DAMPs), including
endogenous danger signals from dead and dying cells [63]. Toll-like receptors (TLRs) are the are the
best characterized PRRs, and the triggering of TLRs upon ligand binding results in signaling events
that lead to the expression of immune response genes, including inflammatory cytokines, stimulatory
immune cytokines and chemokines, which augment the killing of pathogens and initiates the process
of developing acquired immunity [64]. However, data arising from human patients and animal models
of autoimmune disease suggest that continuous activation or dysregulation of TLR signaling might
contribute to the pathogenesis of autoimmunity and tissue damage [65]. Given the important role in
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autoimmunity TLRs and their signaling pathways have emerged as appealing targets for therapeutics.
Understanding how regulators of the actin cytoskeleton, like Flii, contribute to TLR signaling and
inflammatory responses in autoimmune diseases like, EBA, may be important for development of
novel therapeutics for autoimmune disease.
Flii down-regulates IL-1/TLR4 signalling of Toll-like receptor (TLR) pathways [61] by interacting
directly with MyD88, an intracellular adaptor protein immediately downstream of most TLRs [61,64].
TLRs are key innate immune receptors that alert the immune system to tissue damage and mediate the
inflammatory response [66]. MyD88 functions to recruit multiple proteins to precisely control signal
transduction. A novel switch-on, turn-off mechanism of cytoskeletal regulation of TLR signalling
involving Flii has been proposed [61,64]. Flii binds to MyD88 and the Toll/IL-1 receptor domain
(TIR) of the TLR molecules to regulate activation of NF-κB, which controls DNA transcription and
immune responses to infection [61,64]. By looking at Flii interactions with MyD88, its binding
strength and competition with other MyD88 binding partners including Flightless Leucine Rich
Repeat Associated Protein-1 and -2 (FLAP-1 and FLAP-2) it has been suggested that Flii may regulate
TLR functions [61,64]. The temporal and dynamic nature of specific Flii interactions with other
proteins of the TLR signalling has further identified Flii as a negative regulator of the TLR4 signalling
pathway [61,64,67]. Another role for Flii in the immune system has been illustrated by its regulation
of the pro-inflammatory caspases, namely caspase-1 and caspase-11 [68]. Flii modulates the activity
and intracellular localization of these caspases, distributing caspases to the actin network at the
leading cell front where they cleave and activate pro-inflammatory cytokines, including IL-1β and
IL-18 [68]. In addition, silencing of Flii abrogates the inhibitory effect of LRRFlP2 (FLAP-2) on NLRP3
inflammasome activation in macrophages, suggesting a role for Flii as a mediator of inflammation [37].
The function of extracellular Flii has been linked to its LRR domain as it has nearly 50% homology to
the extracellular pathogen binding portion of TLR4 and can bind LPS leading to altered macrophage
activation and subsequent cytokine production [54] (Figure 3).
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Figure 3. Schematic diagram of Flii involvement in inflammation. Flii is secreted in response to
injury/LPS stimulation and current in vitro studies suggest that Flii can dampen TLR inflammatory
pathway both extracellularily an intracellularily resulting in decreased TLR signalling, and
pro-inflammat ry cytokine production. Th effects f Flii as a ediator of inflammati n in the
context of EBA have yet to be investigated. Red arrow pointing down means decreased, and red
cross means inhibited.
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7. Role of Flightless I (Flii) in the Inflammatory Autoimmune Disease EBA
Increased expression of Flii leads to thinner and more fragile skin with impaired hemidesmosome
structure, decreased COL7 expression at the basement membrane and altered arrangement of COL7
anchoring fibrils [13,69] all features often observed in patients with skin blistering [70]. While Flii
over-expressing mice have a normal life expectancy and do not display a blistering phenotype, the
effects of Flii on skin architecture were shown to contribute to decreased cell adhesion, irregular
hemidesomosome structure, decreased COL7 expression, altered integrin signalling, impaired focal
adhesion turnover and increased skin blistering in experimental models of EBA [12,48,69]. In blistered
skin, Flii was found to associate with AP-1 proteins, c-fos and c-jun and affect downstream TGF-β
signalling [12] suggesting that an interplay between Flii and TGF-β may contribute to increased
skin blistering in Flii overexpressing mice. Therefore Flii effects on destabilising the adherence of
epidermis to dermis, via its effects on hemidesmosomes, integrin activation, paxillin phosphorylation,
TGF-β signalling as well as possible interaction with COL7 autoantibodies, may be a key to increased
blistering observed in Flii overexpressing mice (Figure 4). Over expression of Flii resulted in severe
blistering post induction of EBA, while in contrast, decreased expression of Flii impaired blister
formation in experimental EBA by elevating integrin expression, reducing TGF-β mediated collagen
contraction and α-SMA production, reducing Smad signalling and improving COL7 production [12].
These studies point to an important function for Flii in de-stabilising the epidermal-dermal adherence
during skin blistering.
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Figure 4. Flii effects on skin blistering i EBA. Intracellularily, Flii associates with intracellular proteins
and regul tes cell integrin activity and adhesion. In blistered skin, Flii regulates TGF-β signalling
which may contribute to increased disadhesion of skin layers. Flii is a secreted protein and has been
suggested to be involved in later resolving stages of blister healing. Flii’s possible interaction with Col7
autoantibodies may contribute to increased blistering observed in Flii transgenic mice, identifying Flii
as an important modulator of skin blistering in EBA.
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Flii is increased in the blistered skin of patients with different subtypes of hereditary epidermolysis
bullosa particularly in dystrophic epidermolysis bullosa where a genetic decrease in COL7 expression
results in severe skin blistering similar to that observed in EBA [12]. Flii is also detected in human blister
wound fluid at similar levels to those observed in acute and chronic wound fluid [52]. Flii expression
remains elevated in blister wound fluid for up to three days post blistering [13] and elevated Flii
delays the recovery of skin barrier function with decreased Claudin-1 and Claudin-4 expression
following blister healing [15]. Taken together these studies suggest that Flii may be involved in the
later stages of blister healing and that up regulation of Flii is either related to tissue injury or its
effects on regulating inflammation in experimental EBA. Widespread chronic blistering in EBA may
further trigger the elevation of pro-inflammatory cytokines through TLR signalling [71] resulting
in increased elevation of Flii as observed in blister fluid in order to combat increased inflammation.
The effects of Flii on TLR signalling in EBA patients or inflammation mediated skin blistering are yet
to be determined. Studies to date suggest that Flii effects on adherence of skin layers may override its
pro-resolving anti-inflammatory effects during skin blistering. Nonetheless, these studies demonstrate
a relationship between Flii and skin blistering, and suggest that modulation of Flii may improve
skin-blistering outcomes.
In contrast, mice with reduced Flii expression exhibit improved rate of wound healing, enhanced
epithelial migration and increased wound contraction [72]. Flii effects on collagen secretion, cytokine
production and angiogenesis have been described in chronic diabetic and burn injury wounds
modes [73,74] and these chronic conditions may be underpinned by Flii effects on tissue inflammation.
8. Therapeutic Antibodies for Treatments of Autoimmune Skin Conditions
Emerging treatments for EBA, have focused on different pathophysiologic events associated with
this disease including: antibody binding, proinflammatory milieu, blister formation and wound
healing [11]. These approaches have identified number of drugs/antibodies and targets aimed
at directly or indirectly affecting the clinical efficiency of T cells, B cells, neutrophils as well as
mechanisms associated with autoantibody production or wound healing [11]. The use of antibodies
to treat autoimmune skin conditions is one of those approaches. Declizumab, a humanized murine
monoclonal anti-Tac antibody, showed a good response in one patient with inflammatory EBA [75].
More successful was the use of Rituximab, a chimeric, monoclonal antibody against CD20, a cell
surface marker expressed on pre-B cells and mature B cells, which has been used in 12 patients with
EBA and shown promising results for patients with either severe and/or relapsing EBA [4]. In addition,
a recent study using an immunisation-induced EBA model has shown that use of GM-CSF neutralising
antibodies to block inflammation mediated inflammatory cell influx and TLR signalling affected both
autoantibody production and skin blistering in a prototypical organ-specific autoimmune disease [76].
Under development is also the use of anti-Hsp90 in a clinical setting, as experimental models
of autoimmune bullous diseases have revealed that blockade of Hsp90 underlies the multimodal
anti-inflammatory mechanisms of interference with key contributors to auto-immune mediated blister
formation [77,78].
A detailed overview of therapeutic options under development has recently been reviewed [11],
and here we focus on therapeutic antibody approaches related to actin cytoskeletal regulation of
inflammation. Namely, Flii neutralising antibodies have been evaluated in both small and large
preclinical animal models of wound healing, burn injury and diabetes and have demonstrated
that reducing Flii expression improves both the rate and quality of healing [79]. The use of
monoclonal antibody approaches as treatment modalities for improved wound healing have been
used previously [80] and in EBA, Flii neutralising antibodies when applied prior to, during, and after
blister formation reduces both the incidence and severity of blistering in mouse models [13]. FnAbs,
applied topically to the skin, penetrate into the basal epidermis and upper papillary dermis, but are
not detected in serum or other organs and do not alter initial neutrophil or macrophage infiltration into
the blistered skin [13]. Histological assessment of blister severity showed that treatment of early-stage
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blisters, or established blisters with FnAb cream reduced the blister severity, improved the rate of
healing and restored the skin’s tensile strength toward that of normal skin [13]. The effect of FnAb
on the healing of EBA blisters is presented in Figure 5. Future research in this area may lead to novel
therapeutic options in a clinical setting.
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resolution of blister healing in inflammation mediated autoimmune skin conditions such as EBA. 
Strategies, including therapeutic antibodies, have recently emerged, and future research will uncover 
exact mechanisms and pathways affected by some of these pharmacological compounds. Current 
potent efficacy of some of these compounds, including FnAb, in experimental EBA supports their 
introduction into clinical settings, giving patients hope for options other than conventional 
immunosuppressive treatments, however safety profiles or some of these drugs will need to be further 
investigated or improved. In terms of cytoskeletal regulation of inflammation in autoimmune disease, 
Flii seems to be leading target for improved wound repair. Understanding the mechanisms that 
underpin the loss of immune regulation which results in the production of autoimmune disease and 
imbalance of pro-inflammatory stimuli, anti-inflammatory stimuli and resolving pathways in EBA 
are clearly required to help improve the chronic morbidity and mortality of inflammation mediated 
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compared to unwounded skin and a single FnAb applicati n effectively reduces Flii expression in
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9. Futur Directions
The cytoskeleton is intrinsically involved in all aspects of inflammation including inflammatory
cell migration, adhesion into affected areas and regulation of cytokine production and cell signalling.
Cytoskeletal proteins have multiple roles acting in a tim and cell specific manner and an dampen
inflammation both inside and outside of the cell and adversely affe t the development and/or
resolution of blister healing in inflammation mediated autoimmune skin conditions such as EBA.
Strategies, including therapeutic antibodies, have recently emerged, and future research will
uncover exact mechanisms and pathways affected by some of these pharmacological compounds.
Current potent efficacy of some of these compounds, including FnAb, in experimental EBA supports
their introduction into clinical settings, giving patients hope for options other than conventional
immunosuppressive treatments, however safety profiles or so e of these drugs will need to be further
investigated or improved. In terms of cytoskeletal regulation of inflammation in autoimmune disease,
Flii seems to be leading target for improved wound repair. Understanding the mechanisms that
underpin the loss of immune regulation which results in the production of autoimmune disease and
imbalance of pro-inflammatory stimuli, anti-inflammatory stimuli and resolving pathways in EBA
are clearly required to help improve the chronic morbidity and mortality of inflammation mediated
autoimmune disorders.
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